Anti-KIR antibody enhancement of anti-lymphoma activity of natural killer cells as monotherapy and in combination with anti-CD20 antibodies.
about
Immune checkpoint inhibitors: the new frontier in non-small-cell lung cancer treatmentUnderground Adaptation to a Hostile Environment: Acute Myeloid Leukemia vs. Natural Killer CellsTargeting NK Cells for Anticancer Immunotherapy: Clinical and Preclinical ApproachesNK Cells in HIV DiseaseImmune Checkpoint Modulators: An Emerging Antiglioma ArmamentariumNK Cell and CD4+FoxP3+ Regulatory T Cell Based Therapies for Hematopoietic Stem Cell EngraftmentNovel cancer antigens for personalized immunotherapies: latest evidence and clinical potentialNatural Killer Cell Immunomodulation: Targeting Activating, Inhibitory, and Co-stimulatory Receptor Signaling for Cancer ImmunotherapyThe Application of Natural Killer Cell Immunotherapy for the Treatment of CancerEnhancing Cancer Immunotherapy Via Activation of Innate ImmunityImmunotherapy in the treatment of non-small cell lung cancerThe Evolving Role of Immune Checkpoint Inhibitors in Cancer TreatmentHuman NK Cell Subsets Redistribution in Pathological Conditions: A Role for CCR7 ReceptorManufacturing Natural Killer Cells as Medicinal ProductsFeatures of Memory-Like and PD-1(+) Human NK Cell SubsetsImmunological and Translational Aspects of NK Cell-Based Antitumor ImmunotherapiesNivolumab in melanoma: latest evidence and clinical potentialPhase I clinical trial of autologous NK cell therapy using novel expansion method in patients with advanced digestive cancerMechanisms of action of therapeutic antibodies for cancerSelection of an HLA-C*03:04-Restricted HIV-1 p24 Gag Sequence Variant Is Associated with Viral Escape from KIR2DL3+ Natural Killer Cells: Data from an Observational Cohort in South AfricaImmune checkpoint inhibitors in clinical trialsCALGB 150905 (Alliance): rituximab broadens the antilymphoma response by activating unlicensed NK cells.Ex vivo-expanded natural killer cells demonstrate robust proliferation in vivo in high-risk relapsed multiple myeloma patientsNK cell-based immunotherapies in Pediatric Oncology.Present and Future of Allogeneic Natural Killer Cell TherapyKiller-cell Immunoglobulin-like Receptor (KIR) gene profiles modify HIV disease course, not HIV acquisition in South African women.Natural killer cell therapy in children with relapsed leukemia.Cancer immunotherapy: Strategies for personalization and combinatorial approaches.Antibody-Dependent Cellular Cytotoxicity Activity of a Novel Anti-PD-L1 Antibody Avelumab (MSB0010718C) on Human Tumor Cells.The role of checkpoints in the treatment of GBMThe favorable role of homozygosity for killer immunoglobulin-like receptor (KIR) A haplotype in patients with advanced-stage classic Hodgkin lymphoma.Immune based therapy for melanomaHaploidentical Natural Killer Cells Infused before Allogeneic Stem Cell Transplantation for Myeloid Malignancies: A Phase I Trial.Non-myeloablative allogeneic hematopoietic stem cell transplantation for adults with relapsed and refractory mantle cell lymphoma: a single-center analysis in the rituximab eraEffects of anti-NKG2A antibody administration on leukemia and normal hematopoietic cellsAnti-CD137 enhances anti-CD20 therapy of systemic B-cell lymphoma with altered immune homeostasis but negligible toxicity.PD1 blockade enhances cytotoxicity of in vitro expanded natural killer cells towards myeloma cells.Deciphering the killer-cell immunoglobulin-like receptor system at super-resolution for natural killer and T-cell biology.Clinical utility of natural killer cells in cancer therapy and transplantation.A brief personal history of cancer immunotherapy at Stanford: if these walls could talk….
P2860
Q26738359-78DCD6C6-2755-469A-8D14-B14FFFCD1C65Q26751011-01B3F975-8E62-4CC6-BF78-3F6CF5ED676BQ26752518-4C928409-8559-46DE-9146-C435F3493C9EQ26752833-7B328FD2-79C8-4769-8F80-4AEF40E91A5CQ26765459-49AF3E49-0CD5-4CBA-A5E2-25E63B375CD5Q26765845-B024610D-937B-480C-9BDB-4A617FA9BD78Q26769884-2903D16A-D5EA-4A5D-BC83-CA5CB5135537Q26772347-6CD0ADDA-003F-4DEE-951C-1CBCF98ED3BAQ26774678-4642CB66-8F5A-45D6-96F2-D02A0BFD9C3AQ26796313-146F1F8E-A92B-4C3F-BBE7-362430266FA2Q27000382-CA6EB5F3-3D54-474B-9448-74FC09563668Q27022789-AA574D7E-7644-46E4-AB88-E01F4AC5C89EQ28067468-24360366-238C-427A-8B7C-5B28BCA65CEFQ28069992-C912C444-3F64-4574-BD28-7B1025275318Q28073988-9F384CBD-2747-4376-B9A9-8F9D1F3226FAQ28079180-20990647-B99D-41C1-A5D2-B47068BBF3E6Q28258598-A555BD1A-0D18-480A-A92A-7FC43B961934Q28266580-34822730-C5D8-4F56-8CEB-F22F38BE572DQ28385366-C0C5A3BC-A565-4459-8892-918CD2A75305Q28607344-92F14CE5-53CD-44E0-9BB0-7D9BDCD38A51Q34309394-FE60E9CB-BAC3-47AF-8127-77FEE10B2881Q34688644-51432B3B-6254-4890-A60F-20DE5693119AQ35157421-56FC8CF1-3779-447E-A732-C5BBD263C172Q35600975-3CD83C70-7A79-4615-B480-9CE6889E2C8AQ35677351-46149EB5-E12D-42E5-9D16-B1A5D3F1C8F2Q35904239-AF33FE23-BB4F-471F-BA9D-E1C186A9DCCDQ36251948-FE9FBCCD-398A-4A84-A402-F24D6EBA96EFQ36387028-419069D4-0A2B-49D5-9B48-D4BD9B4C4F3DQ36539682-74DC4623-B8EB-4058-AA7C-B24B628AB32CQ36571197-A9FED742-A5FD-47BA-BDC9-4591B5A5292FQ36691438-2BAB831F-49D1-45CE-B3F4-AED6D4ECAAAFQ36876757-315C5241-523E-47E8-8BB9-C65E1DD2EF3EQ36999109-CBC6707D-AC2C-473E-B32A-E00AE6910411Q37071972-A01684B0-BB35-40A5-BB87-E19E9D24782BQ37216218-07FFB6FD-6673-46AA-9C79-1070FC865D93Q37222143-3E121C02-C737-4225-9295-1C081ACE120DQ37565475-6E420697-B9C2-4A61-810D-71BF05E23B19Q37622486-A0B1B8EA-6AF0-43EE-AA65-CA2305D3F236Q38195120-A747706B-362B-49F3-B341-6E8E3351DA90Q38206719-4A79A4F1-57DD-4849-8F30-73AD9071E85F
P2860
Anti-KIR antibody enhancement of anti-lymphoma activity of natural killer cells as monotherapy and in combination with anti-CD20 antibodies.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 10 December 2013
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Anti-KIR antibody enhancement ...... ion with anti-CD20 antibodies.
@en
Anti-KIR antibody enhancement ...... ion with anti-CD20 antibodies.
@nl
type
label
Anti-KIR antibody enhancement ...... ion with anti-CD20 antibodies.
@en
Anti-KIR antibody enhancement ...... ion with anti-CD20 antibodies.
@nl
prefLabel
Anti-KIR antibody enhancement ...... ion with anti-CD20 antibodies.
@en
Anti-KIR antibody enhancement ...... ion with anti-CD20 antibodies.
@nl
P2093
P2860
P1433
P1476
Anti-KIR antibody enhancement ...... ion with anti-CD20 antibodies.
@en
P2093
Amanda Rajapaksa
Ariane Thielens
Aurelien Marabelle
Caroline Sola
Cécile Bonnafous
Debra Czerwinski
Erin Waller
Fabien Chanuc
François Romagné
Holbrook E Kohrt
P2860
P304
P356
10.1182/BLOOD-2013-08-519199
P407
P577
2013-12-10T00:00:00Z